Walmart has settled the federal government's opioid lawsuit, ending a legal battle that began in 2020 over alleged Controlled Substances Act violations. The retail giant, whose stock stood at $103.08, did not disclose the settlement amount, leaving investors unable to assess the financial impact. The Justice Department had accused Walmart of knowingly filling invalid prescriptions, though a judge dismissed several claims. This settlement follows Walmart's $3.1 billion agreement in 2022 to resolve separate opioid claims from state and local governments, a sum that represented about 56% of its latest quarterly free cash flow of $5.5 billion. With the stock trading just 0.14% above its GF Value of $102.94, the undisclosed cost remains a key uncertainty for investors.
Walmart Inc.Walmart settles federal opioid lawsuit with undisclosed cost, adding financial uncertainty.
NVIDIA Corporation